APOE 2, 3, and 4: What the Three Versions of This Gene Actually Do
Three versions of one gene, separated by two amino acids — and why that small difference sends Alzheimer’s risk in three different directions.
Three versions of one gene, separated by two amino acids — and why that small difference sends Alzheimer’s risk in three different directions.
The widely quoted APOE ε4 risk figures come almost entirely from people of European ancestry. How much the numbers change elsewhere, and the haplotype explanation for why.
A randomized phase 2a trial of 49 patients in Nature Medicine found intravenous mesenchymal stem cells slowed whole-brain volume loss by 48.4% in mild Alzheimer’s disease — while the cognitive endpoint’s confidence interval crossed zero. That trial is the entire controlled evidence base for this category. What, then, about the intrathecal infusions, umbilical and Wharton’s jelly preparations, exosome drips, and peptide protocols marketed to ε4 carriers?
A minority of APOE ε4 homozygotes reach advanced age without dementia. This review examines the distinction between resistance to amyloid pathology and resilience despite it, the protective variants and mechanisms implicated to date, and what these exceptional cases do — and do not — establish about modifiable risk in ε4/ε4 carriers.
An Alzheimer’s blood biomarker and an APOE genotype test answer fundamentally different clinical questions: one indicates whether disease pathology is present now, the other estimates lifetime susceptibility. This article explains what each test can establish, what neither can, and how the two are interpreted together.
A patient-facing explanation of the muscle-brain axis — how skeletal muscle signals to the brain during exercise, which effects have human evidence behind them, and what remains extrapolated from preclinical work for APOE ε4 carriers specifically.
Cardiovascular risk factors are among the most consistently modifiable contributors to dementia risk, but the magnitude of benefit is not uniform across APOE genotypes. A physician’s guide to lipid management, blood pressure, and vascular optimization with the genotype-stratified evidence foregrounded.
Sleep is among the few modifiable factors with a direct mechanistic link to Alzheimer’s pathology, including glymphatic clearance of amyloid. This review covers sleep architecture, obstructive sleep apnea, and the genotype-stratified evidence most relevant to APOE ε4 carriers.
A guide to the multidisciplinary team — physicians, neuropsychologists, care navigators, social workers, and community organizations — who support patients and families after a dementia diagnosis, plus practical steps for locating a geriatric psychiatrist and a social worker.
Anti-amyloid therapy eligibility, ARIA risk, genetic counseling, lifestyle intervention, and advance care planning for APOE ε4 carriers newly diagnosed with mild or mild-to-moderate dementia.